“No need for a reunion show: This seasons Real Housewives of Biopharma comes to a close with Pfizer’s winning bid for Metsera ...

Novo Nordisk today presented data at the 76th annual American Association for the Study of Liver Diseases (AASLD) meeting, ...

Despite President Trump’s claims, scientists don’t have enough evidence to say acetaminophen use during pregnancy is linked ...

Here are some of the stocks making notable moves in Monday's premarket action: TreeHouse Foods shares are surging 19% after the food and beverage company agreed to be taken private by Industrial F&B ...

Metsera shares fell significantly as the firm accepted a $10 billion offer from Pfizer, ending its bidding war with Novo Nordisk. Despite the dip, Metsera shares have surged since Pfizer's initial ...

Poviztra to be sold as 2.4 mg injectable; Emcure becomes first Indian firm with exclusive semaglutide distribution rights ...

Novo Nordisk stock rose 2.6% after withdrawing from a $10 billion bidding war for Metsera that investors viewed as too ...

Investing.com -- Metsera Inc. (NASDAQ:MTSR) stock tumbled as much as 16% to $70.15 in premarket trading Monday after Novo Nordisk A/S (NYSE:NVO) abandoned its pursuit of the US weight-loss drug ...

Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, ...

Metsera shares fell sharply in premarket trading Monday after the weight-loss drug startup struck a revised deal to be acquired by Pfizer, prompting Danish drugmaker Novo Nordisk to drop out of a ...

Novo Nordisk launched Wegovy in India in June, three months after Eli Lilly introduced its competing weight-loss product ...

Pedersen COPENHAGEN (Reuters) -Shares in Novo Nordisk rose on Monday after the Wegovy maker lost out to Pfizer in a $10 ...